Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Δ9-THC or (R)-methanandamide (AM-356)

Psychopharmacology

Volumn 188, Issue 3, 2006, Pages 315-323

  Järbe, Torbjörn U C ^a,d   Lamb, Richard J ^b   Liu, Qian ^c   Makriyannis, Alexandros ^d  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

9 THC; Anandamide analogs AM 1346 and AM 356, i.e., (R) methanandamide ; Drug discrimination; Rats; SR 141716A

Indexed keywords

AM 1346; ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; DEXAMPHETAMINE; DRONABINOL; METHANANDAMIDE; MORPHINE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; DEXTROAMPHETAMINE; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; INJECTIONS, INTRAPERITONEAL; MALE; MORPHINE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; REGRESSION ANALYSIS; REINFORCEMENT SCHEDULE; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 33748656277     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0517-x     Document Type: Article

References (42)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893
2. Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217
3. 9-tetrahydrocannabinol: complete generalization with methanandamide. Pharmacol Biochem Behav 79:431-437
4. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62
5. Barrett RL, Wiley JL, Balster RL, Martin BR (1995) Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology 118:419-424
6. 9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther 309:86-91
7. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology 153:67-84
8. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287:884-888
9. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
10. Browne RG, Weissman A (1981) Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21(Suppl):227S-234S
11. 9-THC in a drug-discrimination procedure. Exp Clin Psychopharm 5:195-202
12. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87
13. Extance K, Goudie AJ (1981) Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology 73:363-371
14. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung M, Martin BR, Abood ME (1999) Evaluation of the cannabinoid receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377:117-125
15. Hajos N, Freund TF (2002) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121:73-82
16. Houston DB, Howlett AC (1998) Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal9:667-674
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
18. Järbe TUC, Mathis DA (1992) Dissociative and discriminative stimulus functions of cannabinoids and cannabinergics. In: A Bartke, L Murphy (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, FL, pp 425-459
19. Järbe TUC, Swedberg MDB, Mechoulam R (1981) A repeated tests procedure to assess onset and duration of the cue properties of (-)-delta-9-THC, (-)-delta-8-THC-DMH and (+)-delta-8-THC. Psychopharmacology 75:152-157
20. Järbe TUC, Hiltunen AJ, Lander N, Mechoulam R (1986) Cannabinergic activity (delta-1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav 25:393-399
21. Järbe TUC, Hiltunen AJ, Mechoulam R (1989) Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-OH-delta-8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 250:1000-1005
22. 9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology 140:519-522
23. 9- THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav Pharmacol 11:81-86
24. 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 156:369-380
25. Järbe TUC, DiPatrizio NV, Li C, Makriyannis A (2003a) The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 75:809-821
26. 9-THC induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol 466:121-127
27. 9-THC and (R)-methanandamide in rats. Psychopharmacology 184:36-45
28. Makriyannis A, Goutopoulos A (2004) Cannabinergics: old and new therapeutic possibilities. In: Makriyannis A, Biegel D (eds) Drug discovery strategies and methods 1. Marcel Dekker, New York, pp 89-128
29. Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A, Hanoune J (2002) Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 292:231-235
30. Mukhopadhyay S, Howlett AC (2005) Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67:2016-2024
31. National Institutes of Health (1996) Principles of animal laboratory care. National Academy Press, Washington, DC
32. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324
33. Solinas M, Goldberg SR (2005) Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology 179:804-812
34. Solinas M, Zangen A, Thiriet N, Goldberg SR (2004) β-Endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur J Neurosci 19:183-192
35. Thakur GA, Nikas SP, Li C, Makriyannis A (2005) Structural requirements for cannabinoid receptor probes. In: Pertwee R (ed) Handbook of experimental pharmacology, volume 168. Springer, Berlin, Heidelberg, New York, pp 209-246
36. 2 receptors. Science 310:329-332
37. Weissman A (1978) Generalization of the discriminative stimulus properties of delta-9-tetrahydrocannabinol to cannabinoids with therapeutic potential. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier/ North Holland Biomed Press, Amsterdam, pp 99-122
38. Wiley JL, Martin BR (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121:57-63
39. Wiley J, Balster R, Martin B (1995) Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276:49-54
40. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin B (1997) Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol Biochem Behav 58:1139-1144
41. Wiley JL, Ryan WJ, Razdan RK, Martin BR (1998) Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. Eur J Pharmacol 355:113-118
42. 9 tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol 12:173-179